Overview
IDEX Q3 sales rose 10% to $879 mln, beating analyst expectations
Adjusted EPS for Q3 was $2.03, exceeding analyst estimates
Company increased share repurchase authorization to $1 bln
Outlook
IDEX narrows full-year 2025 GAAP EPS to $6.35 - $6.40
Company maintains full-year 2025 organic sales growth at approximately 1%
IDEX expects at least 100% free cash flow conversion for full year 2025
Result Drivers
ACQUISITION IMPACT - Mott acquisition significantly boosted sales, especially in Health & Science Technologies
SEGMENT PERFORMANCE - Higher volumes in Health & Science Technologies and Fluid & Metering Technologies offset by declines in Fire & Safety/Diversified Products
COST CONTAINMENT - Operational productivity improvements and cost containment actions supported results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Beat | $878.70 mln | $862.27 mln (10 Analysts) |
Q3 Adjusted EPS | Beat | $2.03 | $1.93 (10 Analysts) |
Q3 EPS | $1.70 | ||
Q3 Adjusted Net Income | Beat | $152.80 mln | $148.91 mln (6 Analysts) |
Q3 Adjusted EBITDA | Beat | $239.80 mln | $208.35 mln (2 Analysts) |
Q3 Adjusted Gross Margin | 44.50% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the industrial machinery & equipment peer group is "buy"
Wall Street's median 12-month price target for IDEX Corp is $197.00, about 15.3% above its October 28 closing price of $166.95
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago
Press Release: ID:nBw7Qrqn7a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)